Abstract: Objective To retrospectively analyze the efficacy and safety of camrelizumab combined with anlotinib in patients with intermediate-advanced （BLCL stage B/C） liver cancer who had progressed after systemic therapy. Methods A total of 136 patients who were collected from The Tianyou Hospital Affiliated to Wuhan University of Science and Technology, and Renmin Hospital Affiliated to Wuhan University with pathological diagnosis of primary hepatocellular carcinoma （HCC） from October 2019 to October 2021, and divided into three groups, camrelizumab combined with anlotinib treatment group, anlotinib treatment group, camrelizumab treatment group, through systematic evaluation on a regular basis, collect overall survival （OS）, progression-free survival （PFS）, objective response rate （ORR）, disease control rate （DCR） and other index data for efficacy evaluation and adverse reaction classification; through chi-square test and survival analysis （P<0.5） method for significance analysis. Results In the combination therapy group, the median OS of patients was 15.5 months, the median PFS was 9.5 months, and the ORR was 20.5%, DCR was 95.2%; treatment-related adverse events （AE） were mainly concentrated in grade 1 and grade 2, and the incidence of grade 3 to grade 4 was less than 5%; obviously better than the control group. Conclusions Camrelizumab combined with anlotinib in the treatment of patients with intermediate-advanced （BLCL stage B/C） primary liver cancer has a significant curative effect and controllable safety.